Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
| NCT ID | NCT03065062 |
| Title | Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors |
| Recruitment | Recruiting |
| Gender | both |
| Phase | Phase I |
| Variant Requirements | Yes |
| Sponsors | Dana-Farber Cancer Institute |
| Indications | |
| Therapies | |
| Age Groups: | senior | adult |
| Covered Countries | USA |
| Facility | Status | City | State | Zip | Country | Details |
|---|---|---|---|---|---|---|
| Massachusetts General Hospital | NOT_YET_RECRUITING | Boston | Massachusetts | 02114 | United States | Details |
| Beth Israel Deaconess Medical Center | NOT_YET_RECRUITING | Boston | Massachusetts | 02115 | United States | Details |
| Dana Farber Cancer Institute | RECRUITING | Boston | Massachusetts | 02115 | United States | Details |